Fat Loss Stack

This stack's effectiveness stems from targeting complementary fat loss mechanisms simultaneously. Semaglutide works centrally through the GLP-1 pathway, binding to receptors in the hypothalamus to suppress appetite whilst slowing gastric emptying. Research demonstrates up to 15% body weight reduction over 68 weeks, primarily through reduced caloric intake rather than metabolic changes.

AOD-9604 operates peripherally, mimicking the fat-burning effects of human growth hormone without affecting blood glucose or IGF-1 levels. Studies indicate it specifically targets abdominal fat deposits through enhanced lipolysis and reduced lipogenesis. The peptide's selectivity for adipose tissue makes it an ideal complement to semaglutide's appetite suppression.

Tesamorelin completes the stack by stimulating endogenous growth hormone release, which becomes crucial during caloric restriction. Clinical trials show significant reductions in visceral adipose tissue whilst preserving lean body mass. The growth hormone elevation helps maintain metabolic rate, preventing the adaptive thermogenesis that typically sabotages weight loss efforts.

The synergy is particularly powerful: semaglutide creates the caloric deficit, AOD-9604 mobilises stored fat for energy, and tesamorelin prevents metabolic slowdown whilst targeting problematic visceral fat. This multi-pathway approach addresses both the psychological and physiological challenges of sustained fat loss.

Semaglutide Protocol: Start at 0.25mg subcutaneously once weekly, increasing by 0.25mg every 4 weeks until reaching 1-2.4mg weekly. Inject into abdomen, thigh, or upper arm, rotating sites. Best taken same day each week, with or without food.

AOD-9604 Protocol: 250-500mcg subcutaneously daily, preferably in the morning on an empty stomach. Inject into abdominal area for targeted effect. Some users prefer 5 days on, 2 days off to prevent receptor desensitisation. Cycle for 8-12 weeks followed by 4-week break.

Tesamorelin Protocol: 2mg subcutaneously daily, injected in the evening to align with natural growth hormone pulses. Rotate injection sites across abdomen. Cycle 6 months on, 1 month off to maintain effectiveness. Take on empty stomach, avoid eating for 2 hours post-injection.

Reconstitution and Storage: All peptides require proper reconstitution with bacteriostatic water. Use our reconstitution calculator for precise measurements. Store reconstituted peptides refrigerated at 2-8°C, protected from light. Semaglutide maintains stability for 8 weeks, whilst AOD-9604 and tesamorelin should be used within 4 weeks.

Injection Technique: Use 31-gauge insulin syringes for comfort. Inject at 90-degree angle into subcutaneous tissue. Allow peptides to reach room temperature before injection to reduce discomfort. Maintain sterile technique throughout.

Weeks 1-2: Initial appetite suppression from semaglutide becomes apparent, with users reporting 30-50% reduction in food cravings. Mild nausea possible as body adjusts. Weight loss of 1-2kg primarily from reduced caloric intake and initial water weight.

Weeks 3-8: AOD-9604 begins mobilising fat stores, particularly around midsection. Tesamorelin starts optimising growth hormone levels, improving sleep quality and recovery. Combined weight loss of 3-6kg with noticeable reduction in waist circumference.

Month 2: Synergistic effects become pronounced. Users report sustained energy despite caloric restriction, indicating preserved metabolic rate from tesamorelin. Body composition improvements visible with maintained muscle mass alongside continued fat loss.

Month 3+: Peak effectiveness achieved with potential 8-15% body weight reduction. Visceral fat significantly reduced, metabolic markers improved. Users often report enhanced insulin sensitivity and improved cardiovascular health markers. Maintenance phase focuses on sustaining results through lifestyle integration.

Semaglutide: Most common side effects include nausea (affecting 20-40% of users), vomiting, diarrhoea, and constipation. These typically diminish after 2-4 weeks. Rare but serious risks include pancreatitis and thyroid C-cell tumours in animal studies.

AOD-9604: Generally well-tolerated with minimal side effects reported in clinical trials. Occasional injection site reactions or mild fatigue. No significant impact on blood glucose or hormone levels.

Tesamorelin: Potential side effects include injection site reactions, joint pain, and peripheral oedema. May cause insulin resistance in predisposed individuals, requiring blood glucose monitoring.

Contraindications: Avoid if pregnant, breastfeeding, or planning pregnancy. Not suitable for individuals with history of pancreatitis, thyroid cancer, or severe gastroparesis. Diabetics require careful monitoring as semaglutide affects blood sugar levels.

Peptide research remains ongoing in the UK. Consult our UK peptide legality guide for current regulatory status and ensure proper medical supervision throughout your protocol.